Gain Therapeutics (GANX) Revenue & Revenue Breakdown
Gain Therapeutics Revenue Highlights
Latest Revenue (Y)
$55.18K
Gain Therapeutics Revenue by Period
Gain Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $55.18K | -60.62% |
| 2022-12-31 | $140.11K | -15.08% |
| 2021-12-31 | $164.99K | 471.29% |
| 2020-12-31 | $28.88K | -30.07% |
| 2019-12-31 | $41.30K | 100.40% |
| 2018-12-31 | $20.61K | - |
Gain Therapeutics generated $55.18K in revenue during NA 2023, up -60.62% compared to the previous quarter, and up 267.75% compared to the same period a year ago.
Gain Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $64.80K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | -100.00% |
| 2023-03-31 | $55.18K | -60.62% |
| 2022-12-31 | $140.11K | 100.00% |
| 2022-09-30 | - | -100.00% |
| 2022-06-30 | $95.10K | 111.31% |
| 2022-03-31 | $45.01K | 23.84% |
| 2021-12-31 | $36.34K | 32.90% |
| 2021-09-30 | $27.34K | -69.33% |
| 2021-06-30 | $89.17K | 1592.41% |
| 2021-03-31 | $5.27K | -42.35% |
| 2020-12-31 | $9.14K | 36.48% |
| 2020-09-30 | $6.70K | 5.07% |
| 2020-06-30 | $6.37K | -4.50% |
| 2020-03-31 | $6.67K | 100.00% |
| 2019-12-31 | - | -100.00% |
| 2019-09-30 | $10.32K | - |
| 2019-06-30 | $10.32K | - |
| 2019-03-31 | $10.32K | 100.40% |
| 2018-09-30 | $5.15K | - |
| 2018-06-30 | $5.15K | - |
| 2018-03-31 | $5.15K | - |
Gain Therapeutics generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Gain Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| NAMS | NewAmsterdam Pharma Company | $14.09M | $1.40M |
| MOLN | Molecular Partners | $7.04M | $2.74M |
| CUE | Cue Biopharma | $5.49M | $1.72M |
| INBX | Inhibrx | $1.80M | - |
| MNOV | MediciNova | $1.00M | - |
| TFFP | TFF Pharmaceuticals | $733.87K | $650.22K |
| LIFE | aTyr Pharma | $353.00K | $235.00K |
| GANX | Gain Therapeutics | $55.18K | - |
| ANEB | Anebulo Pharmaceuticals | - | - |
| BIVI | BioVie | - | - |
| INAB | IN8bio | - | - |
| CYT | Cyteir Therapeutics | - | - |
| ELYM | Eliem Therapeutics | - | - |
| CELC | Celcuity | - | - |
| MACK | Merrimack Pharmaceuticals | - | - |
| ELVN | Enliven Therapeutics | - | - |
| LTRN | Lantern Pharma | - | - |
| CSBR | Champions Oncology | - | $12.02M |
GANX Revenue FAQ
What is Gain Therapeutics’s yearly revenue?
Gain Therapeutics's yearly revenue for 2023 was $55.18K, representing a decrease of -60.62% compared to 2022. The company's yearly revenue for 2022 was $140.11K, representing a decrease of -15.08% compared to 2021. GANX's yearly revenue for 2021 was $164.99K, representing an increase of 471.29% compared to 2020.
What is Gain Therapeutics’s quarterly revenue?
Gain Therapeutics's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a -100.00% decrease year-over-year (Q1 2023). GANX's quarterly revenue for Q4 2023 was $64.8K, a 100.00% increase from the previous quarter (Q3 2023), and a -53.75% decrease year-over-year (Q4 2022).
What is Gain Therapeutics’s revenue growth rate?
Gain Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -66.56%, and for the last 5 years (2019-2023) was 33.60%.